James B. Bucher's most recent trade in Zentalis Pharmaceuticals Inc was a trade of 100,000 Stock Option (Right to Buy) done . Disclosure was reported to the exchange on Jan. 8, 2026.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Zentalis Pharma Inc | James B. Bucher | Chief Legal Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 08 Jan 2026 | 100,000 | 100,000 | - | - | Stock Option (Right to Buy) | |
| Zentalis Pharma Inc | James B. Bucher | Chief Legal Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Oct 2025 | 400,000 | 400,000 | - | - | Stock Option (Right to Buy) | |
| Climb Bio Inc | James B. Bucher | EVP and General Counsel | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 Oct 2022 | 95,000 | 95,000 | - | - | Stock Option (Right to Buy) | |
| Climb Bio Inc | James B. Bucher | EVP and General Counsel | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 27 Jan 2022 | 95,000 | 95,000 | - | - | Stock Option (Right to Buy) |